Pharmacology for Nurse Prescribing

Pharmacology for Nurse Prescribing

Adverse Reactions, Pharmacovigilance and Interactions Adverse Reactions Any substance introduced into the body can pose a risk at normal doses, and all are potentially toxic if given in overdose However, we should keep in mind that the great majority of treatments are safe and effective if the principles of pharmacology and pharmacokinetics are carefully applied

We will discuss risk in terms of side-effects, adverse drug reactions, and toxicity Side-effects A consequence of the pharmacological mechanism of action of the drug usually due to presence of receptors in a number of tissues or lack of receptor specificity Examples include drowsiness with the older

antihistamines, constipation with opioids etc. In some situations, a side-effect can be a therapeutic effect e.g. antihistamines for sedation, opioids for diarrhoea Adverse Drug Reactions (ADRs) An ADR is any response to a drug that is undesirable and unintended and that occurs at doses used in humans, for prophylaxis, diagnosis or therapy, excluding therapeutic failure

WHO definition Types of ADRs Type A Predictable ADRs: Predicted from pharmacological reaction and are usually dose-related (eg bradycardia from beta-blocker) Type A by far the majority of ADRs encountered in clinical practice

With careful selection of drug, dose etc. many Type A ADRs can be avoided Types of ADRs cont. Type B: Unpredictable ADRs: Unpredictable from pharmacology of drug and are not dose-dependent; can be very serious May not be picked up in clinical trials if low incidence

Often involve hypersensitivity reactions (eg penicillin anaphylaxis, malignant hyperthermia of anaesthesia, agranulocytosis with clozapine) Sometimes reclassified as Type A after a period of clinical use if mechanism is elucidated Incidence of ADRs Many surveillance studies have been performed both in hospital and community

In addition meta-analyses and systematic reviews ADRs responsible for hospital admissions average about 5% (range 2-12%); in the community the range is far greater (2-40%) reflecting the complexity of data gathering and the criteria used Incidence of ADRs cont. In both cases, the great majority of ADRs

were deemed preventable The economic costs of ADRs are very high Patient Risk Factors for ADRs Age (young, elderly, renal/hepatic function) Disease State e.g. CHF, HIV Gender:

females approx. 1.5 x greater risk Patient Risk Factors for ADRs cont. Genetics: different phenotypes for handling drugs Immunological factors: some patients hypersensitive Number of drugs patient is taking: an obvious risk

factor, especially in the elderly Drug Risk Factors for ADRs Narrow therapeutic index e.g. digoxin, lithium Route of administration e.g. iv drugs can produce immediate effects Formulation/bioavailability: previously

as discussed Drug Risk Factors for ADRs cont. Additives/excipients: patients may be hypersensitive to these rather than the active drug In general, patients may not receive sufficient information about side-effects, ADRs etc. in advance

Identification of ADRs Establishing causal relationships difficult Accurate drug history required (including nonprescription and complementary products Temporal relationship needs to be established (many ADRs can be delayed reactions) Identification of ADRs cont. Detailed

medical history required Dechallenge and rechallenge may or may not be possible (or ethical!) ADR examples Iron containing preparations given orally

GI irritation and pain Nausea appears to be dose related Altered bowel habit, either diarrhoea or constipation These side effects can occur at common therapeutic doses Choice of which Iron preparation prescribed should be guided by that individuals response to that particular preparation (try a fully funded type first) ADR examples Vitamin

A containing preparations Rough skin Dry hair Enlarged liver Teratogenic These adverse reactions only occur at very large doses (e.g. several times usual therapeutic dose)

Pharmacovigilance ADR reporting systems Followed from thalidomide tragedy in 1960s Data on safety gathered by pharmaceutical companies from pre-clinical testing, clinical trials and postmarketing surveillance studies (case studies, cohort studies, case-control studies etc.)

Also several national reporting systems Voluntary Reporting Scheme in NZ Reporting form in MIMS etc Sent to Centre for Adverse Reaction Monitoring (CARM) - based at University of Otago Reports

assessed by Medical Assessor, with reference to prescribers, to produce a database of ADRs Voluntary Reporting Scheme in NZ Reports to Medicines Adverse Reactions Committee at MoH Annual A report by Medsafe

good scheme but main problem with all voluntary schemes is under-reporting Intensive Reporting Intensive Medicines Monitoring Programme (IMMP); also based at Otago A small number (about six see MIMS) of newly marketed medicines on the scheme at any one time Intensive Reporting cont.

All prescriptions for patients on these agents are followed pharmacist records kept Successful in early identification of new ADRs (e.g. ACE inhibitor cough) Only a handful of such schemes worldwide, NZ reputation very high Poisoning (Toxicology)

Due to toxic effects (overdosage) of drugs and other agents Both accidental and deliberate causes Children at special risk especially of Iron or Paracetamol overdose Drugs often in combinations, making treatment difficult High number of acute medical admissions

Treatment: non-specific measures Maintenance of ventilation/blood pressure Reducing absorption - emptying stomach by emesis or washouts - substances to bind poison Increasing elimination - renal elimination by altering pH of urine - haemoperfusion

Ensure hydration, electrolyte balance Individual Agents contd. Paracetamol - causes liver damage which may be fatal, due to production of toxic metabolite when normal liver enzyme system is saturated (at about 10g of paracetamol). Methionine (orally) or n-acetylcysteine (infusion) may be effective antidotes if administered early

Iron - iron chelating agent desferrioxamine IV as antidote Drug Interactions Mostly drug-drug interactions (DDIs), but Also drug-food, drug-alcohol interactions

Dont forget complementary therapies and non-prescription medicines Not all DDIs are bad e.g. sometimes we use a DDI to enhance effects of one of the agents Estimated approx. 20% of ADRs due to DDIs Drug Interactions cont. Many theoretical interactions but really we

want to know those of therapeutic significance Many clinically important drug interactions involve the effect of one drug on the metabolism of another Drug-nutrient interactions Specific drug-nutrient interactions listed in Dietitians New Zealand Inc. Clinical Handbook Interaction

explained briefly, including a mechanism and a practical recommendation Several other interaction texts exist including Stockleys Drug Interactions Object or Precipitant Drug whose effect or action is altered by introduction of another agent is the object drug Drug

which alters or precipitates a change in the effect of the other drug is the precipitant drug Any Particular Drugs? Special care must be taken with patient on low therapeutic index/steep dose-response curve medicines (consider how these medicines will mix with what you are prescribing):

Digoxin Lithium Warfarin Aminoglycosides Cytotoxics Levodopa Verapamil Sulphonylureas More Drugs of Concern Patient dependent on therapeutic effect:

Immunosuppressants (e.g. cyclosporin) Glucocorticoids Oral contraceptives Antiepileptics Antipsychotics Antiarrhythmics Antiretrovirals Enzyme inducers or inhibitors:

Inhibitors e.g. cimetidine, erythromycin Inducers e.g. barbiturates, antiepileptics, rifampicin Mechanisms 1. Pharmaceutical incompatabilities 2. Pharmacodynamic interactions 3. Pharmacokinetic interactions (ADME) 1. Pharmaceutical Incompatibilities Occur before drugs introduced to the body e.g. absorption of benzodiazepines onto rubber, or absorption of carbamazepine to an enteral feed tube

Often involves precipitation of additives to intravenous fluids and other formulations e.g. precipitation of certain antibiotics in IV fluids, neomycin in aqueous cream etc. Exposure time and number of drugs mixed important Usually picked up by pharmacist or checking BNF etc. 2. Pharmacodynamic Interactions

Direct competition at receptor sites - salbutamol/metoprolol - morphine/naloxone Additive effects at receptor sites - e.g. use of two NSAIDs concurrently 2. Pharmacodynamic Interactions cont. Indirect effects at site of action

- amiloride plus potassium supplements (hyperkalaemia) - NSAIDs and warfarin (increased risk of bleeding) 3. Pharmacokinetic Interactions Absorption Chelation describes the process where two separate parts of a mixture will bind strongly to each other Many metal ions (as supplements or antacids ) will bind drugs, thereby preventing them from being

absorbed. E.g. antacids, Ca or Fe containing products given at the same time as doxycycline will prevent absorption of the antibiotic. 3. Pharmacokinetic Interactions cont. Absorption - Gastric emptying and motility Drugs with anticholinergic effects (e.g, tricyclic antidepressants) reduce gastric emptying and decrease bioavailability of levodopa Metoclopramide increases gastric emptying and speeds absorption of paracetamol Pharmacokinetic Interactions cont.

Distribution Generally not clinically significant Pharmacokinetic Interactions cont. Metabolism The great majority of drug interactions of clinical significance involve the effect of one drug on the metabolism of another Phase I metabolosm in the liver is mediated through the Cytochrome P450 mixed oxidase system

In fact Cytochrome P450 is comprised of nearly 60 isoenzymes, each expressed from an individual gene We are just starting to elucidate the importance of genetic determination of each individuals CYP profile CYP Profiling Four main families of CYP450 enzymes

Divided into sub-families; Sub-family enzymes numbered For example CYP1A2 etc. It is beyond this course to give further detail but CYP2D6 is well studied and shows inter-individual variability and CYP3A4 is involved in the metabolism of many drugs (it is found both in liver and intestinal epithelium) Enzyme Inhibitors

Well known enzyme inhibitors include cimetidine; erythromycin, clarithromycin; ciprofloxacin; azoles e.g. fluconazole; allopurinol, antivirals By inhibiting CYP enzymes, they will reduce the metabolism of object drugs using the same metabolic pathway Enzyme Inhibitors cont. If

the object drug has a low therapeutic index then adverse effects may occur For example, if warfarin is the object drug, the risk of bleeding is markedly increased due to rise in blood levels of warfarin (not being metabolised) Similar concerns apply to theophylline, cyclosporin, phenytoin, ocs etc. as object drugs

Enzyme Inducers Well known enzyme inducers include rifampicin, barbiturates, carbamazepine, phenytoin, St Johns Wort; also alcohol and cigarette smoking Involves production of additional enzyme so takes place gradually over several days or weeks Enzyme Inducers cont. Enzyme

induction increases metabolism of the object drug and decreases its pharmacological effects For therapeutically important object drugs (e.g. cyclosporin, oral contraceptives, corticocosteroids, warfarin) there is a risk of therapeutic failure Pharmacokinetic Interactions cont. Excretion Changes in urinary pH - At alkaline pH weak acids are not reabsorbed and

therefore excreted (eg salicylates) - At acid pH weak bases are not reabsorbed and therefore excreted (eg amphetamines) - Urine acidification or alkalinisation used to treat poisoning or to try to mask drugs used in sports or for illicit drug screening! Pharmacokinetic Interactions cont. Excretion Changes in active excretion - some drugs compete for the same active transport system in the kidney tubule - examples include probenecid (excreted preferentially) and penicillins or antiretrovirals; methotrexate and NSAIDs (excreted preferentially)

Drug-Food, Drug-Alcohol Interactions Grapefruit contains flavonoids (CYP3A4 inhibitor in intestine) increases bioavailability of felodipine, statins Alcohol and CNS drugs (additive or synergistic effects with tricyclics, sedatives, opioids etc.) Complementary

medicines (eg St Johns Wort) enzyme inhibitor: care with cyclosporin etc. Drug-Food, Drug-Alcohol Interactions cont. Vit K Warfarin (antagonism of warfarin effects) MAOIs and certain foods containing tyramine (cheese etc.) increase blood pressure

Disulfiram, metronidazole and alcohol (build up of acetaldehyde due to alcohol dehydrogenase inhibition)

Recently Viewed Presentations

  • World Space Programs

    World Space Programs

    German rocket scientists from Operation Paperclip…1946 World Space Programs Today Austria Australia Brazil Canada Chile China Czech Rep Europe France Germany Hungary India Indonesia Iran Iraq Israel Italy Japan Kazakhstan Luxembourg Malaysia Mexico Multi-national North Korea Norway Pakistan Philippines Portugal...
  • The Judicial Branch

    The Judicial Branch

    The Judicial Branch Finding Justice in Society

    Definitive Databases: Using the Library Catalogue as a Database A-Z. Toby Hanning and Gary Steele. Presenter Name. Presentation Title
  • eReaders in the Academic Library Richard Hayman Reference

    eReaders in the Academic Library Richard Hayman Reference

    eBooks in Canadian Academic Libraries. Expenditures on Electronic. Monographs as % of Total. Monographs. PRINT MONOGRAPHS. 12.7 87.3. In Canadian academic libraries, expenditures on electronicmonographs as a percentage of total monographs is 12.7% on average (mean).

    The Trivium style of teaching recognizes that children generally follow a predictable pattern of learning as they grow, and working within this pattern allows teachers to maximize their efforts. This pattern is made up of three stages: grammar, logic, and...
  • Forest Management -

    Forest Management -

    Parts of a Tree Root System Trunk Crown Root System Function of Roots Anchor and support the tree Take in water and nutrients from the soil Help to hold soil in place and improve soil quality Store manufactured food Root...
  • A Clinical Framework for Assessing Function

    A Clinical Framework for Assessing Function

    A Clinical Framework for Assessing Function Dan Parkinson, PT, MBA Director of Clinical Services The International Classification of Function, Disability and Health (ICF) The ICF is structured around the following components: Body Functions and Structure (impairment) Activities and Participation (related...
  • IDPH Uniform Practitioner Orders for Life-Sustaining Treatment (POLST)

    IDPH Uniform Practitioner Orders for Life-Sustaining Treatment (POLST)

    Can Sign Medical Order . are . Expanded. 6. IDPH Uniform "POLST form" The form started in 2000 as the original "orange DNR form" and has gone through a number of changes over the years to reach its current status...